Bespak

Activities: Packaging Drug Delivery Pharmaceutical

Trending Articles

  1. Lonza appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer As of 1 July 2025, Andreas joins Lonza’s Executive Committee as Chief Legal & Corporate Affairs Officer
  2. Famar Group acquires German sterile injectable production site from MiP Pharma The fill-finish facility will enhance Famar's footprint in aseptic and lyophilised therapeutic production, allowing the company to better serve its European clients
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    How to protect your workers with emergency showers In manufacturing environments where chemical exposure is a constant risk, the safety and well-being of your workforce should be a top priority, reports James Hamilton, Global...
  4. SCHOTT Pharma delivers strong second quarter of fiscal year 2025 SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today published its results for the second quarter of the fiscal year 2025
  5. Next generation module improves flow process automation Vapourtec unveils Reaction Controller and Datalogger module

Upcoming event

CPhI North America

20–22 May 2025 | Exhibition | Pennsylvania, US See all

Related Content

Manufacturing

Bespak completes first life cycle assessment for pMDI valve, BK357

The pressurised metered dose inhaler (pMDI) is designed to deliver APIs to the respiratory system in tandem with low global warming potential (GWP) propellants
Manufacturing

Bespak completes construction of inhaler manufacturing facility at its Holmes Chapel, UK facility

The facility now hosts a cGMP Grade D cleanroom and a high-speed commercial aerosol mixing and filling line for the manufacture of pMDIs
Drug Delivery

Bespak and OzUK extend their joint capacity in early-stage pMDI development

The partnership will streamline the pMDI development, testing and pilot scale manufacturing processes to rapidly progress inhaled therapeutics into clinical trials
Sustainability

Bespak and Orbia Fluor & Energy Materials partner to create climate-friendly inhalers

The two companies will create pMDIs with an optimised sustainability profile with Orbia's low global warming potential (GWP) propellant, Zephex 152a
Manufacturing

Bespak and H&T Presspart announce availability of GMP pilot line for climate-friendly pMDIs

Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze
Manufacturing

Bespak reaches milestone in pMDI manufacturing facility expansion

The company has fitted a novel manufacturing line that can produce pMDI products at its Holmes Chapel, UK site
Sustainability

Bespak separation from Recipharm to focus on the transition to low GWP pMDIs

The spin-out has created a global CDMO focused on drug-device combination products and drug delivery devices for pulmonary and nasal inhalation
Subscribe now